We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $977M
1-Year Est. Return 110.37%
This Fund
S&P 500
This Quarter Est. Return
-3.4%
1 Year Est. Return
+110.37%
3 Year Est. Return
+306.38%
5 Year Est. Return
+741.86%
10 Year Est. Return
–
AUM
$970M
AUM Growth
-$80.8M
Cap. Flow
+$19.9M
Cap. Flow %
2.05%
Top 10 Hldgs %
34.67%
Holding
117
New
17
Increased
44
Reduced
27
Closed
27

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$35.1M
2
PTCT icon
PTC Therapeutics
PTCT
+$19.2M
3
NVST icon
Envista
NVST
+$18.5M
4
SYK icon
Stryker
SYK
+$17.7M
5
ABBV icon
AbbVie
ABBV
+$16.6M

Top Sells

Rank Stock Value
1
MASI
Masimo
MASI
+$26M
2
TERN
Terns Pharmaceuticals
TERN
+$25.1M
3
FOLD
Amicus Therapeutics
FOLD
+$21.2M
4
MCK icon
McKesson
MCK
+$21.1M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 99.48%
2 Miscellaneous 0.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMPS
76
Compass Pathways
CMPS
$1.9B
$3.07M 0.32%
554,411
+454,939
+457% +$3.06M
DRUG
77
Bright Minds Biosciences
DRUG
$714M
$2.93M 0.3%
+40,098
New +$3.23M
SLDB icon
78
Solid Biosciences
SLDB
$1.05B
$2.22M 0.23%
308,844
-109,527
-26% -$704K
BFLY icon
79
Butterfly Network
BFLY
$2.24B
$2.2M 0.23%
544,477
+443,642
+440% +$1.71M
QDEL icon
80
QuidelOrtho
QDEL
$1.01B
$1.67M 0.17%
101,764
-82,727
-45% -$2.03M
RXST icon
81
RxSight
RXST
$293M
$1.54M 0.16%
249,989
-101,666
-29% -$844K
QTRX icon
82
Quanterix
QTRX
$125M
$1.2M 0.12%
341,453
+12,497
+4% +$72.9K
PLSE icon
83
Pulse Biosciences
PLSE
$3.39B
$1.08M 0.11%
+50,125
New +$925K
LUNG icon
84
Pulmonx
LUNG
$102M
$975K 0.1%
755,636
+27,855
+4% +$46K
MAZE
85
Maze Therapeutics
MAZE
$1.52B
$951K 0.1%
31,844
-177,422
-85% -$7.83M
ADMA icon
86
ADMA Biologics
ADMA
$2.09B
$743K 0.08%
82,443
-117,557
-59% -$1.86M
FOCL
87
EDAP TMS S.A.
FOCL
$198M
$576K 0.06%
154,832
– –
OVID icon
88
Ovid Therapeutics
OVID
$547M
$462K 0.05%
208,205
+7,169
+4% +$12.8K
ARAY icon
89
Accuray
ARAY
$32.7M
$343K 0.04%
884,578
+32,566
+4% +$20.1K
ENTX icon
90
Entera Bio
ENTX
$525M
$320K 0.03%
288,670
+13,597
+5% +$19.1K
A icon
91
Agilent Technologies
A
$43.4B
– –
-100,000
Closed -$13.6M
ACHC icon
92
Acadia Healthcare
ACHC
$2.66B
– –
-100,000
Closed -$1.42M
ACLX
93
DELISTED
Arcellx
ACLX
– –
-128,111
Closed -$8.35M
BIIB icon
94
Biogen
BIIB
$32.3B
– –
-35,425
Closed -$6.23M
CERT icon
95
Certara
CERT
$1.27B
– –
-348,750
Closed -$3.07M
CRNX icon
96
Crinetics Pharmaceuticals
CRNX
$9B
– –
-22,852
Closed -$1.06M
DAWN
97
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-645,544
Closed -$6.02M
DHR icon
98
Danaher
DHR
$152B
– –
-58,889
Closed -$13.5M
DOCS icon
99
Doximity
DOCS
$4.76B
– –
-162,276
Closed -$7.19M
FOLD
100
DELISTED
Amicus Therapeutics
FOLD
– –
-1,487,283
Closed -$21.2M
1 2 3
4
5

Similar funds

KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
ACM
Arini Captial Management London, United Kingdom $975M AUM
FM
Family Management New York $975M AUM 23.16% 1-Year Est. Return
PAMI
Perseverance Asset Management International George Town, Cayman Islands $979M AUM 50.58% 1-Year Est. Return
PFGIA
Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return
SI
Seeds Investor New York $973M AUM 33.7% 1-Year Est. Return
HIGP
Hill Investment Group Partners St. Louis, Missouri $980M AUM 22.33% 1-Year Est. Return
SCA
Stillwater Capital Advisors Devon, Pennsylvania $981M AUM 31.05% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Parkman Healthcare Partners held 117 positions worth $970M, down 7.7% from $1.05B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Parkman Healthcare Partners's Q1 2026 filing shows 17 new, 44 increased, 27 reduced and 27 closed positions. Its largest new stake was Eli Lilly: 34,616 shares worth $31.8M. The largest sale was Masimo, an estimated $26M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

  • Parkman Healthcare Partners's largest Q1 2026 buy was Eli Lilly: 34,616 shares worth $31.8M.
  • Parkman Healthcare Partners added most to PTC Therapeutics in Q1 2026, an estimated $19.2M increase.
  • Parkman Healthcare Partners's biggest Q1 2026 reduction was McKesson, cutting an estimated $21.1M.
  • Parkman Healthcare Partners fully exited Masimo in Q1 2026, selling an estimated $26M.
  • Parkman Healthcare Partners's ten largest holdings make up 35% of its $970M portfolio in Q1 2026.
  • Parkman Healthcare Partners opened 17 new positions and closed 27 in Q1 2026.
  • Parkman Healthcare Partners's portfolio value fell 7.7% quarter-over-quarter to $970M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.